By Viz.aiLearning Objectives
- Understand what AI care coordination means and how Viz.ai goes beyond detection to action
- Evaluate Viz.ai's 50+ FDA-cleared algorithms across neurology, cardiology, and oncology
- Assess the significance of CMS reimbursement for AI in healthcare
What Is Viz.ai?
Viz.ai is a medical AI platform that detects time-sensitive conditions from imaging — stroke, pulmonary embolism, hemorrhage, aortic aneurysm — and immediately coordinates the care team response. Unlike AI tools that only flag findings, Viz.ai integrates detection with care coordination: automatically notifying the right specialists, routing patients to appropriate facilities, and tracking outcomes.
With 50+ FDA-cleared algorithms deployed across 1,000+ hospitals, Viz.ai was the first AI company to receive CMS New Technology Add-on Payment (NTAP) for its stroke detection — meaning Medicare pays hospitals for using Viz.ai's AI.
Multi-Specialty Coverage
| Specialty | FDA-Cleared Tools |
|---|---|
| Neurology | Stroke (LVO detection — first AI de novo FDA clearance); intracerebral hemorrhage; subdural hemorrhage; cerebral aneurysm |
| Cardiology | Pulmonary embolism; RV/LV analysis; hypertrophic cardiomyopathy (first FDA de novo for HCM) |
| Vascular | Abdominal aortic aneurysm (first FDA-cleared AI for AAA) |
| Oncology | Viz Oncology Suite (launched May 2025) — end-to-end cancer care coordination |
| Pulmonary | Interstitial lung disease detection (IMVARIA partnership, June 2025) |
Company Details
| Detail | Info |
|---|---|
| Founded | 2016 |
| CEO | Chris Mansi, M.D. (co-founder, neurosurgeon) |
| Headquarters | San Francisco, California (offices in Tel Aviv, Amsterdam) |
| Total Raised | $289 million across 10 rounds |
| Valuation | $1.2 billion (April 2022 Series D) |
| Key Investors | Tiger Global; Google Ventures; Kleiner Perkins; Insight Partners |
| Hospitals | 1,000+ |
| FDA-Cleared Algorithms | 50+ |
| CMS NTAP | First AI company to receive Medicare reimbursement |
| Website | viz.ai |
Key Takeaways
- Viz.ai combines AI detection with care coordination — not just flagging findings but automatically notifying specialists and routing patients
- 50+ FDA-cleared algorithms across neurology, cardiology, vascular, oncology, and pulmonary; deployed at 1,000+ hospitals
- First AI company to receive CMS NTAP (Medicare reimbursement) — validating AI as a reimbursable standard of care
